HCP Understanding of the Prevalence of CSID



How Common is Congenital Sucrase-Isomaltase Deficiency?

In one study, the prevalence of individuals with a sucrase activity level below the lower limit of the normal population was estimated to be as high as 8.9% in the United States.1

In a much more recent retrospective survey of nearly 30,000 American cases of mucosal biopsy samples collected during pediatric endoscopies and evaluated using a disaccharidase assay, 9.3% of the samples demonstrated a sucrase deficiency.3

There is wide phenotypic heterogeneity among CSID patients, with a broad spectrum of symptom severity, ranging from absent or minimal to life-threatening. The symptoms of CSID are also nonspecific and often mirror those of other, more common, gastrointestinal (GI) disorders. As such, it is likely that the true prevalence of CSID may be underestimated. Numerous patients who experience chronic diarrhea and/or abdominal pain as a result of CSID may remain undiagnosed.

About CSID - Prevalence Map | HCP Sucraid

Figure 1. Estimated prevalence of CSID in various ethnic populations1

Learn How to Order Sucraid® from Our Specialty Pharmacy

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Do not use Sucraid® (sacrosidase) Oral Solution with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.


Sucraid®(sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).